Modeling the effect of gut microbiome on therapeutic efficacy of immune checkpoint inhibitors against cancer

DOI10.1016/J.MBS.2022.108868zbMATH Open1497.92109OpenAlexW4283322329MaRDI QIDQ2164665FDOQ2164665

Authors: Yanyan Li 

Publication date: 15 August 2022

Published in: Mathematical Biosciences (Search for Journal in Brave)

Full work available at URL: https://doi.org/10.1016/j.mbs.2022.108868

Recommendations

• Response of patients with melanoma to immune checkpoint blockade -- insights gleaned from analysis of a new mathematical mechanistic model
• A mechanistic systems pharmacology modeling platform to investigate the effect of PD-L1 expression heterogeneity and dynamics on the efficacy of PD-1 and PD-L1 blocking antibodies in cancer
• Computational modeling and experimental investigations to enhance the successful response of anti-PD-\(1\) cancer immunotherapies
• Cancer therapy with immune checkpoint inhibitor and CSF-1 blockade: a mathematical model
• Modeling tumour heterogeneity of PD-L1 expression in tumour progression and adaptive therapy

zbMATH Keywords

mathematical modelingpredictive biomarkersimmune checkpoint inhibitorsgut bacteriaanti-tumor efficacy

Mathematics Subject Classification ID

Medical applications (general) (92C50) Microbiology (92C70)

Cites Work

• A methodology for performing global uncertainty and sensitivity analysis in systems biology
• An extended mathematical model of tumor growth and its interaction with the immune system, to be used for developing an optimized immunotherapy treatment protocol
• Mathematical modeling of an immune checkpoint inhibitor and its synergy with an immunostimulant

Cited In (5)

• LRBmat: a novel gut microbial interaction and individual heterogeneity inference method for colorectal cancer
• Mathematical modeling of tumor immune interactions: the role of anti-FGFR and anti-PD-1 in the combination therapy
• A mechanistic systems pharmacology modeling platform to investigate the effect of PD-L1 expression heterogeneity and dynamics on the efficacy of PD-1 and PD-L1 blocking antibodies in cancer
• Optimal control of tumor-lymphatic model with immuno-chemotherapy
• Modeling tumour heterogeneity of PD-L1 expression in tumour progression and adaptive therapy

This page was built for publication: Modeling the effect of gut microbiome on therapeutic efficacy of immune checkpoint inhibitors against cancer

Report a bug (only for logged in users!)Click here to report a bug for this page (MaRDI item Q2164665)